Compare WPRT & PSTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WPRT | PSTV |
|---|---|---|
| Founded | 1995 | 1996 |
| Country | Canada | United States |
| Employees | 112 | N/A |
| Industry | Industrial Machinery/Components | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.8M | 37.2M |
| IPO Year | 2006 | 2016 |
| Metric | WPRT | PSTV |
|---|---|---|
| Price | $1.85 | $5.39 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $4.38 | ★ $55.00 |
| AVG Volume (30 Days) | 23.6K | ★ 130.2K |
| Earning Date | 04-23-2026 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 87.61 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $5,213,000.00 |
| Revenue This Year | N/A | $13.20 |
| Revenue Next Year | $28.74 | $261.48 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.54 | $0.13 |
| 52 Week High | $4.14 | $8.00 |
| Indicator | WPRT | PSTV |
|---|---|---|
| Relative Strength Index (RSI) | 33.56 | 45.74 |
| Support Level | $1.71 | $5.28 |
| Resistance Level | $1.85 | $6.65 |
| Average True Range (ATR) | 0.06 | 0.52 |
| MACD | -0.02 | -0.15 |
| Stochastic Oscillator | 10.68 | 14.61 |
Westport Fuel Systems Inc is an organization engaged in the engineering, manufacturing, and supply of alternative fuel systems and components for transportation applications. It has three reportable segments: High-Pressure Controls, Heavy-Duty OEM, and Cespira. It derives maximum revenue from Heavy-Duty OEM segment. Heavy-Duty OEM segment's products include HPDI related fuel system solutions and components. Geographically, the company operates in Europe, America and Asia, of which it generates maximum revenue from Europe. It also develops and supplies advanced LPG, CNG, LNG and H2 systems and components for OEM (original equipment manufacturer) D-OEM (delayed oem) and After Market (retrofit market) world-wide.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, commercializing and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).